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Background: Tracheal occlusion (TO) stimulates lung growth in fetuses affected with congenital diaphragmatic
hernia (CDH) although the processes involved in lung maturation still remain unknown. The objective of this study
was to evaluate the metabolomic profile of amniotic fluid (AF) following TO in fetal lamb model in order to obtain
an indirect view of mechanisms involved in pulmonary reversal hypoplasia and biochemical maturity in response to
fetal TO.
Methods: Liquid Chromatography Mass Spectrometry was performed on lamb AF samples at: age I (70 days’
gestation); age II (102 days’ gestation); age III (136 days’ gestation). CDH was induced at age I and TO at age II.
Results: Betaine, choline, creatinine were found significantly increased during gestation in the control group. The
CDH group showed choline (p =0.007) and creatinine (p =0.004) decreases during pregnancy. In the TO group
choline and creatinine profiles were restored.
Conclusions: Alveolar tissue and fetal global growth ameliorated after TO. Metabolomics provided useful
information on biochemical details during lung maturation. Metabolomic profiling would help to identify the best
time to perform TO, in order to increase survival of CDH affected patients.
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Congenital diaphragmatic hernia (CDH) is a congenital
birth defect that occurs in 1/2000 to 1/3000 newborns
with a survival rate of 42-68%. Abnormal development
of the pulmonary parenchyma and vasculature lead to
variable degrees of respiratory insufficiency and pulmon-
ary hypertension in early neonatal life [1-4].
While modern neonatal intensive care has improved
the prognosis for surviving cases, comorbidities affect al-
most half of live-born infants and the mortality rate re-
mains high in patients with poor prenatal prognosis.
Experimental studies could potentially ameliorate out-
comes in pulmonary hypoplasia [5,6]. Fetal endoscopic* Correspondence: g.pelizzo@smatteo.pv.it
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unless otherwise stated.tracheal occlusion (FETO) may still be a possible thera-
peutic procedure in case of severe CDH, even if the
mortality rate is reported to be nearly 40% [7-9].
Amniotic fluid (AF) composition reflects the physio-
logical status during fetal development and it may be
used to detect potential pathological conditions. AF con-
tains large amounts of proteins and metabolites pro-
duced by the amnion epithelial cells, fetal tissues, fetal
excretions and placental tissues.
Metabolomics is commonly used to measure the entire
metabolomic profile in biological fluids, cells, tissues or
organs and to elucidate the association between meta-
bolic pathways and perturbations that arise as a result of
disease or organ malformation [10-13].
The objective of this study was to determine amniotic
fluid metabolic profiling changes in fetal lambs who
underwent surgically induced CDH and subsequent tra-
cheal occlusion (TO) which provides an excellent visionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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to determine the real benefits and best timing for TO.
Methods
The experimental protocol was approved by the National
Animal Care and Ethics Committee and was conducted in
accordance with Italian and European legislation (D.lgs.
116/92, European Directives 86/609/EE for the protection of
animals used in scientific and experimental studies and
2010-63UE).
A preliminary study with Liquid Chromatography
Mass Spectrometry (LC-MS) [14,15] was performed on
20 lamb AF samples, taken at three gestational ages: Age
I (70 days’ of gestation); Age II (102 days’ gestation); Age
III (136 days’ gestation).
CDH induction was performed at Age I and TO was
carried out during the 2nd trimester at Age II.
Based on this information, AF samples were divided
into:
– – CONTROL group, healthy control pregnancies:
Age I, number of samples =5; Age II, number of
samples =3; Age III, number of samples =3;
– – CDH group, fetuses with induced CDH: Age II,
number of samples =3 and at Age III, number of
samples =3;
– – CDH + TO group, fetuses with induced CDH and
TO treatment: Age III, number of samples =3
Healthy control AF samples were collected to study
the normal metabolomic evolution.
We report on the effect of induced CDH and TO
treatment for selected metabolites at stage Age III.
Anesthesia protocol
All surgical procedures were performed under general
anesthesia. After premedication with intramuscular (IM)
injection of 5 mg/Kg ketamine and 0.2 mg/Kg midazo-
lam (Dormicum®, Roche), intravenous access (IV) was
established at the external jugular vein.
The pregnant ewes were pre-oxygenated using a face-
mask and induced with 5 mg/Kg IV propophol (Propo-
fol®-Lipuro 1%, B. Braun Melsungen AG). Endotracheal
intubation was performed, and general anesthesia was
maintained with isoflurane 2% (Isoflo, Abbott laboratories
Ltd) in 100% oxygen (1.5 L/minute).
Esophageal intubation was performed to prevent ruminal
bloat. A continuous infusion of Ringer lactate (B. Braun
Melsungen AG) was administered at 10 ml/Kg/h during
surgery. Intra-operative monitoring consisted of electrocar-
diography, pulse oximetry, non invasive blood pressure and
capnography. All animals received a 75 μg transdermal
fentanyl patch (Durogesic®, Janssen laboratories) for
post-operative pain relief. For peri-operative infectionprophylaxis, the animals received a single dose of 22 mg/Kg
IV cephazolin (Kurgan®, Normon Laboratories) at the time
of induction and 15 mg/Kg IM amoxicillin (Duphamox L.
A., Fort Dodge) every 48 h, for eight days. Fetuses were
anesthetized through the placenta and additional anesthesia
with fentanil (10 μg/kg IM) and the muscle relaxant pan-
curonium (0.3 mg/Kg IM) were administered. Meloxicam
0.5 mg/kg IM /24 h was administered as post-operative an-
algesia for seven days. Maternal body temperature was
monitored by using a digital probe and maintained at 36-
37°C with a warming bed. Standard ECG electrodes were
used for monitoring.
Surgical technique
As a first step, malformation was surgically induced (day
70 of gestation). A midline laparotomy exposed the
gravid uterus. The fetus was partially extruded from the
uterus with a short hysterectomy (4 cm). A left fetal
thoracotomy was achieved and a diaphragmatic hernia
was created. The fetal stomach was raised into the
thorax, which was closed into one layer. The fetus was
returned to the uterus (2 gr of amoxicillin were added to
the amniotic fluid). The uterus wall and maternal lapar-
otomy were closed.
The next step included the tracheal occlusion (day 102
of gestation). The uterus was externalized after a midline
laparotomy. The fetal lamb’s mouth was located and also
partially externalized by a short hysterectomy (2 cm). A
latex detachable balloon was placed into the trachea and
inflated. The fetus was returned to the uterus and 2 gr
of amoxicillin were added to the amniotic fluid. Closure
of the uterus and the abdomen walls was performed.
At the end of the pregnancy (day 136 of gestation),
lambs were delivered via terminal caesarean section, ap-
proximately 10 days before term to prevent natural par-
turition. Lambs were euthanized with a bolus of
Pentobarbital 200 mg/Kg IV.
Metabolomic analysis
Sample preparation
Amniotic fluid samples were centrifuged after collection in
order to remove cells and cellular debris. The supernatants
were immediately frozen and stored at -70°C/-80°C until
metabolite extraction and analysis were performed. Super-
natant samples were thawed at room temperature and
methanol extraction was accomplished with the protocol
reported by Graca et al. [16]. An internal standard (2’-deox-
yadenosine) was added to the extracted dry aliquots which
were reconstituted in ultrapure H2O (Milli-Q H2O).
HPLC-TOF-MS analysis
LC-MS analysis was performed by positive ionization
mass spectrometry using a Q-STAR mass spectrometer
(AB-SCIEX, Foster City, CA, USA) equipped with an
Table 2 Metabolite MS peak area (Intensity Counts) in
Age II ovine amniotic fluid
Age II AF MS peak area Fold Difference p
Metabolite Control CDH
Betaine 19140 17905 1.07 0.089
± ±
750 944
Choline 4793 3667 1.31 0.007
± ±
381 118
Creatinine 19988 17115 1.17 0.004
± ±
968 609
Data are expressed as group means ± standard deviations. p refers to
Welch’s ANOVA.
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lyzed using AB-SCIEX Analyst™ QS software (version
1.1). The HPLC system includes an Agilent 1100 series
micro LC pump. The liquid chromatographic separation
was performed on a Jupiter® 5 μm 300 Å (150 × 0.5 mm)
Reverse PhaseC18 column (PhenomenexInc, Torrance,
CA, USA) at a flow of 10 μL/min using a gradient from
0% to 90% of solvent Bover 35 min. Solvents A and
Bconsisted of water and acetonitrile, respectively; both
contained 0.1% (v/v) formic acid. All samples were ana-
lyzed in triplicate.
Metabolites were quantified using LC-MS-TOF stand-
ard runs in positive-ion mode, while LC-MS/MS runs
were used for molecule identification. The assignment of
the metabolites was based on analytical standards ana-
lyzed under the same chromatographic conditions.
Data processing and analysis
The metabolite peaks from raw HPLC-MS chromato-
grams were integrated with the software Analyst QS 1.1
(Applied Biosystems-SCIEX) by evaluating the extracted
ion chromatogram (XIC) counts. All data sets were nor-
malized to account for variable sample dilution and ex-
perimental influences using the peak area of the internal
standard (2’-deoxyadenosine).
The HPLC-MS data shown in Tables 1, 2 and 3 represent
the metabolite XIC areas, which do not account for con-
centrations, but can be used to evaluate the relative level of
each metabolite among the three sample groups (Control
Age I/II/III, CDH Age II/III and CDH+TO Age III).
A comparison of Age II groups (Control II and CDH
II) and among Age III groups (Control III, CDH III and
CDH + TO III) was performed and the One-Way Ana-
lysis of Variance (ANOVA) was applied to determineTable 1 Metabolite MS peak area (Intensity Counts) in
ovine amniotic fluid from a fetal lamb model of
congenital diaphragmatic hernia (CDH) and tracheal
occlusion (TO)
MS peak area
Age I
(70 days)
Age II
(102 days)
Age III
(136 days)
Metabolite Control Control CDH Control CDH CDH + TO
Betaine 7931 19140 17905 91450 17210 27990
± ± ± ± ± ±
426 750 944 2646 566 901
Choline 1500 4793 3667 6281 1639 3933
± ± ± ± ± ±
179 381 118 375 146 14
Creatinine 687 19988 17115 189533 20330 118833
± ± ± ± ± ±
77 968 609 7821 495 3612
Data are expressed as group means ± standard deviation.whether the means of groups significantly differed. We
performed Welch’s ANOVA, which does not assume
constant variance across all groups, with an alpha level
set at 0.05. In the case of Age III, sample differences be-
tween all pairs of groups were compared according to
the Games-Howell method, which does not assume
constant variance while controlling the multiple com-
parisons error rate.
Results
The AF analysis in control samples (gestational Ages I to
III) led to the identification of potentially interesting mole-
cules in the amniotic fluid, including amino acids, organic
acids, sugars and nucleotide metabolites. Among these, we
observed that only three metabolites,betaine, choline and
creatinine, continuously increased during ovine gestation,
while all the other identified metabolites exhibited a vari-
able trend including increasing and decreasing phases. This
made the mentioned metabolites the best biomarkers of a
physiological pregnancy and we therefore focused on these
three compounds and analysed their variation following in-
duced CDH and TO treatment.
According to the ANOVA analysis of age II groups
(102 days), CDH induces a significant decrease in cho-
line (p 0.007) and creatinine (p 0.004), while betaine al-
terations were not significant (p 0.089) (Figure 1 and
Table 1).
The most significant alterations observed were in AF
collected at Age III (136 days), since at this stage the ef-
fect of CDH could be evaluated either with or without
the TO treatment.
The results from non-treated CDH, in comparison with
healthy controls, resulted in the following adjusted p values:
choline (p 0.001), creatinine ( p 0.001) and betaine (p 0.000)
(Figure 1 and Table 2).
Interestingly, the TO treatment led to a substantial re-
covery in choline and creatinine levels and to a modest
Table 3 Metabolite MS peak area (Intensity Counts) in Age III ovine amniotic fluid
Age III AF MS peak area Fold difference Adjusted p t MS peak area Fold difference Adjusted p t MS peak area Fold difference Adjusted p t
Metabolites Control CDH Control CDH + TO CDH + TO CDH
Betaine 91450 17210 5.31 0.000 47.02 91450 27990 3.27 0.000 39.33 27990 17210 1.63 0.001 16.43
± ± ± ± ± ±
2646 566 2646 901 901 566
Choline 6281 1639 3.83 0.001 19.36 6281 3933 1.60 0.015 10.84 3933 1639 2.40 0.042 22.10
± ± ± ± ± ±
375 146 375 14 14 146
Creatinine 189533 20330 9.32 0.001 37.36 189533 118833 1.60 0.002 14.21 118833 20330 5.84 0.001 46.59
± ± ± ± ± ±
7821 495 7821 3612 3612 495
Data are expressed as group means ± standard deviation. Adjusted p and t were obtained with the One-way ANOVA with Games-Howell Pairwise Comparisons.
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Figure 1 Metabolomic data summarized in Table 1. The Interval Plots show the trend exhibited by the three metabolic markers: betaine
(panel A), choline (panel B) and creatinine (panel C) during gestation in the case of “control/CDH induced/CDH induced and TO” treatedfetal
lambs. Bullets represent the group mean values, while the interval bars extend 2 standard errors away from the mean.
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the Age III groups and the following Games Howell
multiple comparison test are consistent with this trend
(Figure 1 and Table 3). In particular, p obtained when
comparing the control and CDH + TO groups indicate
that by the end of gestation, betaine, choline andcreatinine were positively affected by the TO treatment
and resulted closer to the physiological level. In fact, al-
though the p indicate a significant difference between
the control and CDH + TO conditions, the comparison
of fold difference values between control and CDH sam-
ples, with and without TO, show a significant recovery
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(Table 3).
Discussion
Amniotic fluid volume and composition are the result of
the dynamic interaction between the secretion of fetal lung
liquid, fetal urine and the removal of fluid by fetal swallow-
ing and/or resorption through the fetal membranes [17]. A
great amount of AF comes from epithelial lung. Between
47-54% of the lung secreted fluids comes out of fetal tra-
chea and are swallowed and the rest is mixed with the am-
niotic fluid during breathing movements [17].
Metabolomics of human AF has been recently used to
detect different fetal pathologies in pregnancy such as
chromosomal disorders [18-20], renal dysfunction [10,21],
metabolic disease [10], neural tube anomalies [10,22-24]
and defects of intrauterine growth [25-28]. Recent
advances in metabolomics [10-13,29] also introduce AF
evaluation as a new approach to fetal pulmonary develop-
ment studies.
Preliminary data of our study show an interesting in-
crease in choline, betaine and creatinine levels during
physiologic pregnancy. The profile of these metabolites in-
creases constantly during gestational age. These molecules
are detectable in AF in different concentrations, according
to the gestational period [11,12]. Changes in the gestational
choline profile have already been correlated with the fetal
lung maturity [30]. Choline seems to be involved in the syn-
thesis of phospholipid, a major surfactant component. The
role of betaine is unclear; it is formed by choline oxidation
catalyzed by the mitochondrial enzyme choline dehydro-
genase [16,30,31]. Betaine is also engaged in pulmonary de-
velopment in the same metabolic pathway as choline.
Creatinine has also been used long as a test of fetal matur-
ity. Bock showed that in relation to maturity of the fetus,
the relative intensity of the creatinine peak correlated best
with conventional tests of fetal lung maturity [12]. Choline
and creatinine are involved in development of different fetal
organs. The possibility that the profile of these metabolites
may be influenced by other variables, such as the fetal renal
system, cell membrane turnover, cannot be excluded.
Newborns with CDH have hypoplastic lung. These pa-
tients have normal maturation values for alveolar epithelial
type II. At birth, surfactant and phospholipid production is
not delayed [31,32]; the total amount of cells is reduced, as
expected in a hypoplasia condition. Prenatal TO to treat se-
vere CDH seems to improve pulmonary growth [1-4,33,34].
TO prevents egress of pulmonary fluid leading to lung tissue
stretching and reversal of lung hypoplasia. The lung paren-
chymal structure increases in alveolar growth and inter-
alveolar wall thickness. In the animal model, sustained
FETO causes type II cell depletion resulting in significantly
low surfactant production. Temporary FETO fails to cause
lung growth in the CDH model, but it preserves type II cells,surfactant production, and partially corrects abnormal mus-
cularization of pulmonary arterioles seen in pulmonary
hypertension [31-36].
Our study confirms the perturbation of lung maturity in
CDH. Certain AF metabolites stop increasing from stage II
to stage III in CDH fetuses. The intensity peaks of creatin-
ine and betaine at stage III, at the end of gestation, were
similar to those found at stage II but reduced in average
compared to controls at the same gestational age (stage II).
Choline intensity peaks in CDH fetuses were even found to
be significantly lower during gestation than control speci-
mens; growth curve did not increase from the beginning of
gestation and values found at term were lower than those
found in controls at stage I.
In this study, sustained TO was performed to repro-
duce the same conditions induced by FETO in CDH hu-
man fetuses. Surprisingly, fetal TO seems to improve the
profile of the three metabolites: immediately at Age II
after TO induction and at stage III gestation. Creatinine
had the most improved metabolomic recovery profile,
supporting the role of this metabolite as a marker of
lung involvement in fetal development [12,30].
The mild response of betaine, with respect to creatinine
and choline, could be related to the involvement of this me-
tabolite in simultaneous methylation reactions which also
include the development of fetal respiratory system.
Nuclear magnetic resonance (NMR) spectroscopy or
mass spectrometry (MS) are employed to characterize
metabolomic profiles and quantify all small molecules in
biological samples. Thus a comprehensive global moni-
toring of metabolites and their fluctuations in response
to various stimuli can be achieved. Metabolomic profil-
ing can provide information on what is actually changing
in a biological system, and serves as a crucial link be-
tween phenotype and genetics [13-16]. Simultaneous
analysis of different groups of metabolic markers like
amino acids (ie alanine), sugars (ie glucose) and muscle
catabolites (ie creatinine) in a single MR spectrum al-
lows indirect assessment of function and development of
fetal organs [11-13]. The observed variation could also
reflect the AFS cell composition in the AF. In this view,
congenital diaphragmatic hernia could trigger AFS cell
maturation according to tissue regeneration needs,
resulting in a AF metabolic signature in the CHD lamb
model [9].
There are no previous studies on the metabolomic profile
of the amniotic fluid in the CDH lamb model after TO.
This approach provided an indirect index of fetal lung
maturity, but the involvement of surfactant production of
type II cells needs to be verified in further studies. Con-
comitant metabolomics, histological and immunochemical
studies, are needed to confirm a direct correlation between
AF profile, type II pneumocyte integrity and lung matur-
ation before and after TO.
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the hypothesis that the best biomarkers of a physiological
pregnancy may be considered as suggestive indexes of lung
maturity also in CDH fetuses. Increased knowledge of pul-
monary maturation may be useful in defining biochemical
mechanisms which are at the basis of lung hypoplasia in
CDH fetuses. The effects of TO confirm their role in re-
storing the processes involved in surfactant-mediated lung
maturation. This study also supports novelinvestigations in
potential pathways implicated in AF regulatory mecha-
nisms. Intra-tracheal pulmonary absorption could be con-
sidered an influent pathway in the amniotic fluid dynamics.
Conclusions
AF metabolomic profiles may be considered indirect
markers of lung growth and could be useful in defining
the prognosis of CDH fetuses. Metabolomic analysis in
AF in a CDH animal model, provides useful information
on fetal lung biochemical mechanisms involved in pul-
monary development processes.
Further investigations are still needed to identify new
biochemical macromolecules involved in fetal lung mat-
uration to improve survival of severe CDH fetuses.
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